Research programme: antibacterials - Thallion Pharmaceuticals

Drug Profile

Research programme: antibacterials - Thallion Pharmaceuticals

Alternative Names: Antibacterials research programme - Thallion Pharmaceuticals; ECO 00501

Latest Information Update: 25 Aug 2009

Price : $50

At a glance

  • Originator Ecopia BioSciences
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Adverse events, pharmacokinetics and Viral Infections Antimicrobial Activity and pharmacodynamics section ,
  • 16 Sep 2003 Preclinical trials in Bacterial infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top